The latest AI breast cancer identification system, Transpara™ 1.6 will be showcased at RSNA 2019

CHICAGO, Nov. 29, 2019 /PRNewswire-PRWeb/ -- Transpara™ 1.6, the leading Artificial Intelligence decision support system for breast cancer screening, that uses deep learning algorithms to automatically detect potential breast cancer in 2D and 3D DBT mammograms, will be unveiled at the Annual Radiological Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, South Hall #4380).

The software uniquely ranks mammograms on a 10-point scale indicating the short term risk that cancer is present. Independent clinical validations demonstrate that this Transpara Exam Score can reduce workload and help radiologists prioritise patients for further investigation. Interactive decision support is provided to assist radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists , thus acting as a 'second pair of eyes' which increases diagnostic confidence and accuracy .

Transpara is CE Marked for use with 2D mammography and 3D digital breast tomosynthesis (DBT) images from multiple vendors and is installed at leading breast imaging centers in Europe. Transpara is FDA Cleared for use with 2D mammography in the U.S. and is pending FDA Clearance for use with 3D DBT.

"The showcasing of Transpara 1.6 at RSNA demonstrates our focus on continually improving to ensure we can provide our clients with the best commercially available breast AI," said Nico Karssemeijer, CEO for ScreenPoint Medical. "We understand that reading 3D mammography presents radiologists with huge workload and reading time challenges compared to 2D. With feedback from the field, we redesigned the Transpara 1.6 interface and utilised our patented co-registration slice technology to optimise reading workflow and to ensure peace of mind. Users just click on the region of interest on the synthetic 2D image and are immediately taken directly to the exact slice which saves time."

"ScreenPoint's aim is to help radiologists to identify and diagnose breast cancer as early as possible whilst minimizing problems associated with mammography including over-diagnosis. What's exciting about Transpara 1.6 is that there is now evidence to show that it is catching high grade cancers earlier so that treatment can begin earlier and so improve a woman's chances of a cure," said ScreenPoint co-founder, Professor Sir Michael Brady.

Pieter Kroese, COO of ScreenPoint Medical, said: "International interest in the success of the Transpara system has been growing rapidly: Transpara is now being used or piloted in around 20 countries around the world and the feedback from radiologists has been universally positive. We are extremely fortunate to have some excellent partners who have seen at first hand the benefits Transpara can bring to increasingly busy radiologists."

Transpara is marketed in the USA by Siemens Healthineers USA and Volpara Solutions, a wholly owned sales and marketing arm of Volpara Health Technologies.

Following the successful launch of ScreenPoint Medical's medical education program at EUSOBI this year, ScreenPoint is collaborating with Siemens Healthineers for Transpara self-reading workshop sessions (10:15 - 5:00pm, Sunday 1 December -Thursday 5 December) in the North Hall at booth #8563"

Transpara will also be featured in an abstract accepted for presentation: 'Artificial Intelligence Detecting Breast Cancer in a Screening Population: Accuracy, Earlier Detection on Prior Mammograms and Relation with Cancer Grade. Sunday, Dec. 1st 11:55am to 12:05pm in Room S406A.'

About ScreenPoint Medical BV
ScreenPoint Medical is the leading developer of AI driven image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations. With proven accuracy matching that of experienced radiologists, ScreenPoint's Transpara™ system is the most advanced available, exploiting Big Data, Deep Learning and the latest advances in Artificial Intelligence. The system can identify high risk breast lesions quickly, enabling earlier detection, earlier treatment and a greater chance of survival. ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, two internationally respected experts in breast imaging, machine learning and computer aided detection. The company's Head Office is in Nijmegen, The Netherlands. For more information, please email [email protected]

1 "Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists", Rodriguez-Ruiz et al, JNCI: Journal of the National Cancer Institute, djy222, https://doi.org/10.1093/jnci/djy222, 2019..
2 "Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System" Rodríguez-Ruiz et al, Radiology 290:2, 305-314, 2019

#    #    #

*Disclaimer: Transpara is CE marked for 2D and 3D mammography. Transpara is FDA cleared for 2D mammography and currently being assessed for 3D . Not all features are available in all countries. Please check with local representatives.

Media Contact:
Chris K. Joseph
510/435-4031
[email protected]

SOURCE ScreenPoint Medical